2m 2m 2m 2m 2m 2m 2m
- $511.9MMarket Cap
- 24.02%1-Year Change
- Medical Instruments & SuppliesIndustry
AngioDynamics (ANGO)
Key Performance
More- Earnings Score: 68
- Momentum Score: 92
- True Yield: N/A
- Financial Health Score: 44
Latest Research & News
A comprehensive market analysis report on atherectomy devices covering 39 countries with forecasts through 2036. The market is driven by the shift toward minimally-invasive techniques for treating coronary and peripheral artery diseases, replacing traditional bypass surgery. The report provides detailed market segmentation, intervention volumes, competitive dynamics, and regulatory insights across developed markets.
01/16/2026, 5:50 AM • GlobeNewswire
Why AngioDynamics Stock Is Sinking Today
AngioDynamics shares fell 13.1% despite posting strong Q3 results with revenue of $79.4 million (beating estimates) and better-than-expected earnings. The sell-off was triggered by the unexpected announcement of CEO Jim Clemmer's retirement after 10 years leading the company. While the board has formed a search committee to find a successor and the company raised its 2026 guidance, investor uncertainty about leadership transition overshadowed the positive business fundamentals.
01/06/2026, 11:04 AM • The Motley Fool
Why Did AngioDynamics Stock Pop Today?
AngioDynamics reported Q1 fiscal 2026 results with mixed performance, beating adjusted earnings expectations but showing ongoing challenges in profitability. The company saw 12% overall sales growth, driven by med tech segment, but remains years away from consistent profitability.
10/02/2025, 12:28 PM • The Motley Fool
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Key Executives
- James C. Clemmer
- Stephen A. Trowbridge
- Laura Piccinini
- Warren G. Nighan
- Lawrence T. Weiss
Current Ownership Distribution
- Institutions654.5M (74.18%)
- Mutual Funds220.5M (24.99%)
- Insiders7.3M (0.83%)
- Other0 (0.00%)